Brian Till
Expertise in
13
conditions

Dr. Brian Till

Oncology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Offers Telehealth
Expertise in
13
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Brian Till is an Oncologist in Seattle, Washington. Dr. Till is highly rated in 13 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Follicular Lymphoma.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
Office
1959 NE Pacific St # 356340, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
View 1 Less Clinical Trial

94 Total Publications

Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.
Journal: JCO clinical cancer informatics
Published: January 14, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Ajay Gopal
Oncology
Expertise in
22
conditions
Dr. Ajay Gopal
Oncology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is highly rated in 22 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Classical Hodgkin Lymphoma.

Expertise in
19
conditions
Dr. John Pagel
Oncology
Expertise in
19
conditions
Dr. John Pagel
Oncology

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (1.7 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances

John Pagel is an Oncologist in Seattle, Washington. Dr. Pagel is highly rated in 19 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
10
conditions
Dr. Petros Grivas
Oncology
Expertise in
10
conditions
Dr. Petros Grivas
Oncology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-520-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Petros Grivas is an Oncologist in Seattle, Washington. Dr. Grivas is highly rated in 10 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Endoscopy.

Frequently Asked Questions about Dr. Brian Till

How do I make an appointment with Dr. Brian Till?

You can book an appointment with Dr. Brian Till by calling their office at 855-557-0555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian Till a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian Till is classified as an Elite expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian Till specialize in?

While Dr. Brian Till is a Oncology, they have specific expertise in Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Brian Till participate in research or clinical trials?

Yes. Dr. Brian Till has published 94 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Brian Till's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian Till accept my insurance?

Dr. Brian Till accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 855-557-0555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Till's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile